Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:ASBP NASDAQ:IMA NASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$3.08+2.3%$2.14$1.47▼$17.31$73.33MN/A261,855 shs34,682 shsASBPAspire Biopharma$0.35-3.0%$0.35$0.22▼$15.80$18.06M0.794.97 million shs603,114 shsIMAIkena Oncology$16.49-0.7%$16.09$11.65▼$23.28$66.73M0.5147,971 shs18,402 shsPMVPPMV Pharmaceuticals$1.48+2.8%$1.19$0.81▼$1.82$74.81M1.52321,300 shs141,978 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+2.33%+5.84%+87.23%+48.43%-72.25%ASBPAspire Biopharma-2.99%-25.76%+21.13%+35,369,900.00%+35,369,900.00%IMAIkena Oncology-0.66%+8.49%+3.32%+26.07%-15.70%PMVPPMV Pharmaceuticals+2.78%+2.78%+22.31%+66.33%+1.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics2.138 of 5 stars3.50.00.00.00.61.71.3ASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AIMAIkena Oncology3.5038 of 5 stars3.33.00.00.03.53.31.3PMVPPMV Pharmaceuticals2.8128 of 5 stars3.55.00.00.00.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$17.80477.92% UpsideASBPAspire Biopharma 0.00N/AN/AN/AIMAIkena Oncology 2.50Moderate Buy$35.50115.28% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50271.62% UpsideCurrent Analyst Ratings BreakdownLatest ASBP, PMVP, ARTV, and IMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025IMAIkena OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$25.00 ➝ $23.006/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.005/15/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.00(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K300.12N/AN/A$7.68 per share0.40ASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/AIMAIkena Oncology$9.16M7.24N/AN/A$28.83 per share0.57PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%8/7/2025 (Estimated)ASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-508.70%N/AIMAIkena Oncology-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%8/14/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)Latest ASBP, PMVP, ARTV, and IMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IMAIkena Oncology-$0.14N/AN/AN/AN/AN/A8/14/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/7/2025Q2 2025ARTVArtiva Biotherapeutics-$0.77N/AN/AN/AN/AN/A7/24/2025Q2 2025IMAIkena Oncology-$0.14-$0.06+$0.08-$0.06N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/A5/8/2025Q1 2025IMAIkena Oncology-$2.52-$2.16+$0.36-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AASBPAspire BiopharmaN/AN/AN/AN/AN/AIMAIkena OncologyN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A13.9313.93ASBPAspire BiopharmaN/A0.220.22IMAIkena OncologyN/A13.5213.52PMVPPMV PharmaceuticalsN/A16.7516.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AASBPAspire Biopharma19.17%IMAIkena Oncology75.00%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%ASBPAspire Biopharma48.00%IMAIkena Oncology5.94%PMVPPMV Pharmaceuticals7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.36 million19.15 millionN/AASBPAspire BiopharmaN/A49.53 million25.75 millionN/AIMAIkena Oncology704.02 million3.78 millionNot OptionablePMVPPMV Pharmaceuticals5051.95 million48.01 millionOptionableASBP, PMVP, ARTV, and IMA HeadlinesRecent News About These CompaniesBML Capital Management LLC Boosts Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)July 26, 2025 | marketbeat.comRobert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) StockJuly 4, 2025 | insidertrades.comPmv Pharmaceuticals Inc (PMVP) - Investing.comJuly 3, 2025 | investing.comPMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare AdvancesMay 23, 2025 | quiverquant.comQPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comWe're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateMay 18, 2025 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%April 21, 2025 | aaii.comAHere's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingMarch 5, 2025 | zacks.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals sees cash runway to end of 2026March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsMarch 3, 2025 | globenewswire.comPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesFebruary 11, 2025 | globenewswire.comPMV Pharmaceuticals stock hits 52-week low at $1.32January 21, 2025 | msn.comPMV Pharmaceuticals files $200M mixed securities shelfNovember 21, 2024 | markets.businessinsider.comPMV Pharmaceuticals upgraded to Outperform from Perform at OppenheimerNovember 9, 2024 | markets.businessinsider.comPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPMV Pharmaceuticals (PMVP) Gets a Buy from Craig-HallumOctober 25, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)October 25, 2024 | markets.businessinsider.comPMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical TrialOctober 23, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASBP, PMVP, ARTV, and IMA Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$3.08 +0.07 (+2.33%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$2.65 -0.43 (-13.83%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Aspire Biopharma NASDAQ:ASBP$0.35 -0.01 (-2.99%) As of 08/5/2025 03:56 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Ikena Oncology NASDAQ:IMA$16.49 -0.11 (-0.66%) As of 08/5/2025 03:59 PM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.PMV Pharmaceuticals NASDAQ:PMVP$1.48 +0.04 (+2.78%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.50 +0.02 (+1.35%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Soars After Blowout Earnings Report Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? Applied Digital: Why a Surge in Bullish Bets Signals a New Era META Gets Huge Upgrades: How High Analysts Think Shares Could Go Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
